A Phase 2 interventional study of Tovorafenib in Melanoma, Solid Tumor and CRAF Gene Amplification, sponsored by Day One Biopharmaceuticals, Inc.. Terminated at 20 sites in 7 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2025-10-02.
Sponsored by Day One Biopharmaceuticals, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 2,049 studies in Melanoma with a site in United States — 243 open to participants now, 440 under way, 32 of them phase 3. Melanoma · United States.
Among the 2,049 studies in Melanoma with a site in United States, this one is the 1,121st largest by enrollment of the 1,749 interventional ones that give a count, is one of 106 that started in 2021, is one of 612 in phase 2, and was the 1,667th registered.
3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.
Browse Melanoma studies →243 of the 2,049 studies in Melanoma with a site in United States are open now. Recruiting first, the newest first:
Children's Oncology Group · Sites in United States
Ages up to 25
John Kirkwood · Sites in United States
Ages 18+
University of Wisconsin, Madison · Sites in United States
Ages 18+
H. Lee Moffitt Cancer Center and Research Institute · Sites in United States
Ages 18+ · Healthy volunteers
University of Colorado, Denver · Sites in United States
Ages 55+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
2,049 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 934 · Phase 2 907 · Phase 3 115 · Phase 4 11
First in 1991; this study’s year is marked. 106 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 23 is below the median of 40 across 2,651 interventional studies indexed under Melanoma.
Median enrollment 37 across the 1,749 interventional studies, 156 across the 212 observational. Of the 1,481 that completed or were terminated, 598 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
800 of 2,049 have an industry lead sponsor. The 10 most frequent:
Day One Biopharmaceuticals, Inc. is the lead sponsor of 8 studies on the registry; 3 are open to participants now.
Day One Biopharmaceuticals, Inc. has 2 studies filed under Melanoma — fewer than ten, so there is no comparison to draw.
141 of the studies in Melanoma with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05608291Phase 3Regeneron PharmaceuticalsA Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery | 2027-01-15 |
| NCT05987332Phase 3IDEAYA BiosciencesIDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma | 2027-01-15 |
| NCT06246916Phase 3Regeneron PharmaceuticalsA Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head) | 2027-03-22 |
| NCT01223248Phase 3Memorial Sloan Kettering Cancer CenterRandomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy | 2027-10 |
| NCT06112314Phase 3Immunocore LtdIMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) | 2027-10-16 |
Add all 141 to your calendar (.ics) → With an account.
Among the 2,049 studies in Melanoma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 2, multi-center, open-label to evaluate the efficacy and safety of tovorafenib (DAY101) in participants ≥12 years of age with recurrent or progressive melanoma or solid tumors with BRAF fusion or CRAF/RAF1 fusions or amplification.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tovorafenib monotherapy
Drug: Tovorafenib
Tovorafenib monotherapy
Drug: Tovorafenib
Tovorafenib tablet for oral use.
Also known as: DAY101
Overall Response Rate (ORR) by the Investigator
ORR was defined as the percentage of participants with the best overall confirmed response of complete response (CR) or partial response (PR) according to the appropriate response assessment criteria including Response Evaluation Criteria in Solid Tumors (RECIST 1.1) or Response Assessment in Neuro-Oncology (RANO) for the disease setting as assessed by the Investigator. CR or PR was confirmed at a subsequent scan (\>=4 weeks) if the criteria for each are met . The exact 95% confidence intervals (CIs) were calculated using Clopper-Pearson method.
Time frame: Up to 23 months
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
An adverse event (AE) is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An serious adverse event (SAE) is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgment. An AE is considered to be treatment-emergent if it has a start date/time on or after the first administration of study drug until 30 days after the last dose of study drug and before the start of subsequent therapy, whichever comes earlier. The distribution of AEs was analyzed by the type, frequency and severity for TEAEs.
Time frame: Up to 23 months
Number of Participants With Worst Case Hematology Results by Maximum Grade Increase Post-baseline Relative to Baseline
Blood samples were collected for the analysis of following hematology parameters: anemia, neutrophil count decreased and white blood cell decreased. Grade 1 (G1): mild; Grade 2 (G2): moderate; Grade 3 (G3): severe; Grade 4 (G4) life-threatening or disabling. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Any worst-case post baseline increase to G2, G3, and G4 are presented. The laboratory parameters were graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.
Time frame: Baseline and up to 23 months
Number of Participants With Worst Case Chemistry Results by Maximum Grade Increase Post-baseline Relative to Baseline
Blood samples were collected for the analysis of following chemistry parameters: creatine phosphokinase (CPK) increased, hypokalemia, hypoalbuminemia, hypercalcemia, hypocalcemia and hyponatremia. Grade 1 (G1): mild; Grade 2 (G2): moderate; Grade 3 (G3): severe; Grade 4 (G4) life-threatening or disabling. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Any worst-case post baseline increase to G2, G3, and G4 are presented. The laboratory parameters were graded according to CTCAE version 5.
Time frame: Baseline and up to 23 months
Duration of Response (DOR) in Participants With Best Overall Response
Duration of response was defined as the interval from the date of the first documentation of tumor response (CR or PR) that was subsequently confirmed by investigator assessment to the date of first occurrence of radiographic disease progression based on RECIST 1.1 or RANO criteria or death due to any cause, whichever occurs earlier. DOR was estimated using Kaplan-Meier method.
Time frame: Up to 23 months
Duration of Progression Free Survival
Progression free survival was defined as the interval from the date of the first dose to the first occurrence of radiographic disease progression based on RECIST 1.1 or RANO criteria or death due to any cause, whichever occurs earlier. Progression free survival was estimated using Kaplan-Meier method.
Time frame: Up to 23 months
Duration of Overall Survival
Overall survival is defined as the interval from the date of the first dose until the recorded date of death due to any cause. Overall survival was estimated using Kaplan-Meier method.
Time frame: Up to 23 months
Time to Response
Time to Response was defined in participants with best overall response of complete response or partial response as determined by Investigator. It is the interval from the date of the first dose to date of first documentation of tumor response that was subsequently confirmed by investigator assessment.
Time frame: Up to 23 months
This study was conducted at 11 centers that enrolled participants in 6 countries.
| Milestone | Melanoma Cohort | Tissue Agnostic Cohort |
|---|---|---|
| Started | 8 | 15 |
| Completed | 4 | 8 |
| Not completed | 4 | 7 |
| Withdrew: Death | 4 | 6 |
| Withdrew: Withdrawal by subject | 0 | 1 |
ORR was defined as the percentage of participants with the best overall confirmed response of complete response (CR) or partial response (PR) according to the appropriate response assessment criteria including Response Evaluation Criteria in Solid Tumors (RECIST 1.1) or Response Assessment in Neuro-Oncology (RANO) for the disease setting as assessed by the Investigator. CR or PR was confirmed at a subsequent scan (\>=4 weeks) if the criteria for each are met . The exact 95% confidence intervals (CIs) were calculated using Clopper-Pearson method.
| Percentage of participants | Melanoma Cohort | Tissue Agnostic Cohort |
|---|---|---|
| Overall Response Rate (ORR) by the Investigator | 50.0 (15.7 to 84.3) | 40.0 (16.3 to 67.7) |
An adverse event (AE) is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An serious adverse event (SAE) is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgment. An AE is considered to be treatment-emergent if it has a start date/time on or after the first administration of study drug until 30 days after the last dose of study drug and before the start of subsequent therapy, whichever comes earlier. The distribution of AEs was analyzed by the type, frequency and severity for TEAEs.
| Participants | Melanoma Cohort | Tissue Agnostic Cohort |
|---|---|---|
| Any TEAE | 8 | 15 |
| TEAEs Related to Study Drug | 8 | 13 |
| Any serious TEAE | 2 | 8 |
| Serious TEAEs Related to Study Drug | 0 | 1 |
| TEAEs with Severity Grade 3 or Higher | 5 | 8 |
| TEAEs Related to Study Drug with Severity Grade 3 or Higher | 2 | 3 |
| TEAEs Leading to Death | 0 | 0 |
| TEAEs Related to Study Drug Leading to Death | 0 | 0 |
| TEAEs Leading to Study Drug Discontinuation | 1 | 0 |
| TEAEs Related to Study Drug Leading to Study Drug Discontinuation | 1 | 0 |
Blood samples were collected for the analysis of following hematology parameters: anemia, neutrophil count decreased and white blood cell decreased. Grade 1 (G1): mild; Grade 2 (G2): moderate; Grade 3 (G3): severe; Grade 4 (G4) life-threatening or disabling. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Any worst-case post baseline increase to G2, G3, and G4 are presented. The laboratory parameters were graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.
| Participants | Melanoma Cohort | Tissue Agnostic Cohort |
|---|---|---|
| Anemia, Increased to Grade 2 | 3 | 5 |
| Anemia, Increased to Grade 3 | 2 | 2 |
| Anemia, Increased to Grade 4 | 0 | 0 |
| Neutrophil count decreased, Increased to Grade 2 | 0 | 2 |
| Neutrophil count decreased, Increased to Grade 3 | 0 | 1 |
| Neutrophil count decreased, Increased to Grade 4 | 0 | 0 |
| White blood cell decreased, Increased to Grade 2 | 0 | 2 |
| White blood cell decreased, Increased to Grade 3 | 0 | 0 |
| White blood cell decreased, Increased to Grade 4 | 0 | 0 |
Blood samples were collected for the analysis of following chemistry parameters: creatine phosphokinase (CPK) increased, hypokalemia, hypoalbuminemia, hypercalcemia, hypocalcemia and hyponatremia. Grade 1 (G1): mild; Grade 2 (G2): moderate; Grade 3 (G3): severe; Grade 4 (G4) life-threatening or disabling. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Any worst-case post baseline increase to G2, G3, and G4 are presented. The laboratory parameters were graded according to CTCAE version 5.
| Participants | Melanoma Cohort | Tissue Agnostic Cohort |
|---|---|---|
| CPK increased, Increased to Grade 2 | 2 | 4 |
| CPK increased, Increased to Grade 3 | 0 | 1 |
| CPK increased, Increased to Grade 4 | 1 | 0 |
| Hypoalbuminemia, Increased to Grade 2 | 1 | 2 |
| Hypoalbuminemia, Increased to Grade 3 | 0 | 0 |
| Hypoalbuminemia, Increased to Grade 4 | 0 | 0 |
| Hypokalemia, Increased to Grade 2 | 1 | 5 |
| Hypokalemia, Increased to Grade 3 | 0 | 1 |
| Hypokalemia, Increased to Grade 4 | 0 | 0 |
| Hyponatremia, Increased to Grade 2 | 1 | 1 |
| Hyponatremia, Increased to Grade 3 | 0 | 0 |
| Hyponatremia, Increased to Grade 4 | 0 | 0 |
| Hypercalcemia, Increased to Grade 2 | 0 | 0 |
| Hypercalcemia, Increased to Grade 3 | 0 | 1 |
| Hypercalcemia, Increased to Grade 4 | 0 | 0 |
| Hypocalcemia, Increased to Grade 2 | 0 | 1 |
| Hypocalcemia, Increased to Grade 3 | 0 | 0 |
| Hypocalcemia, Increased to Grade 4 | 0 | 0 |
Duration of response was defined as the interval from the date of the first documentation of tumor response (CR or PR) that was subsequently confirmed by investigator assessment to the date of first occurrence of radiographic disease progression based on RECIST 1.1 or RANO criteria or death due to any cause, whichever occurs earlier. DOR was estimated using Kaplan-Meier method.
| Months | Melanoma Cohort | Tissue Agnostic Cohort |
|---|---|---|
| Duration of Response (DOR) in Participants With Best Overall Response | 5.6 (3.0 to NA) | 9.2 (3.5 to NA) |
Progression free survival was defined as the interval from the date of the first dose to the first occurrence of radiographic disease progression based on RECIST 1.1 or RANO criteria or death due to any cause, whichever occurs earlier. Progression free survival was estimated using Kaplan-Meier method.
| Months | Melanoma Cohort | Tissue Agnostic Cohort |
|---|---|---|
| Duration of Progression Free Survival | 5.5 (1.8 to 12.5) | 5.5 (1.7 to NA) |
Overall survival is defined as the interval from the date of the first dose until the recorded date of death due to any cause. Overall survival was estimated using Kaplan-Meier method.
| Months | Melanoma Cohort | Tissue Agnostic Cohort |
|---|---|---|
| Duration of Overall Survival | 18.9 (3.4 to NA) | NA (5.5 to NA) |
Time to Response was defined in participants with best overall response of complete response or partial response as determined by Investigator. It is the interval from the date of the first dose to date of first documentation of tumor response that was subsequently confirmed by investigator assessment.
| Months | Melanoma Cohort | Tissue Agnostic Cohort |
|---|---|---|
| Time to Response | 1.76 (1.66 to 6.44) | 1.82 (1.77 to 1.87) |
Collected over Up to 23 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Melanoma Cohort | 4/8 (50%) | 2/8 (25%) | 8/8 (100%) |
| Tissue Agnostic Cohort | 6/15 (40%) | 8/15 (53.3%) | 15/15 (100%) |
| Event | Melanoma Cohort | Tissue Agnostic Cohort |
|---|---|---|
| EpistaxisRespiratory, thoracic and mediastinal disorders | 1/8 | 0/15 |
| Tumour associated feverNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/8 | 0/15 |
| AnaemiaBlood and lymphatic system disorders | 0/8 | 1/15 |
| EncephalopathyNervous system disorders | 0/8 | 1/15 |
| Haemorrhage intracranialNervous system disorders | 0/8 | 1/15 |
| HemiparesisNervous system disorders | 0/8 | 1/15 |
| HypercalcaemiaMetabolism and nutrition disorders | 0/8 | 1/15 |
| Metastases to lungNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/8 | 1/15 |
| Musculoskeletal chest painMusculoskeletal and connective tissue disorders | 0/8 | 1/15 |
| NauseaGastrointestinal disorders | 0/8 | 1/15 |
| Event | Melanoma Cohort | Tissue Agnostic Cohort |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 5/8 | 7/15 |
| FatigueGeneral disorders | 4/8 | 0/15 |
| MyalgiaMusculoskeletal and connective tissue disorders | 1/8 | 6/15 |
| ConstipationGastrointestinal disorders | 3/8 | 3/15 |
| Face oedemaGeneral disorders | 3/8 | 2/15 |
| PruritusSkin and subcutaneous tissue disorders | 3/8 | 4/15 |
| RashSkin and subcutaneous tissue disorders | 3/8 | 3/15 |
| Blood creatine phosphokinase increasedInvestigations | 1/8 | 5/15 |
| VomitingGastrointestinal disorders | 1/8 | 4/15 |
| AstheniaGeneral disorders | 0/8 | 4/15 |
Safety Analysis Set comprised of all participants enrolled in the study who received at least one dose of study treatment.
| Age, Continuous(Years) | Melanoma Cohort | Tissue Agnostic Cohort | Total |
|---|---|---|---|
| Median | 58.0 (26 to 71) | 45.0 (21 to 71) | 53.0 (21 to 71) |
| Sex: Female, Male(Participants) | Melanoma Cohort | Tissue Agnostic Cohort | Total |
|---|---|---|---|
| Female | 4 | 7 | 11 |
| Male | 4 | 8 | 12 |
| Ethnicity (NIH/OMB)(Participants) | Melanoma Cohort | Tissue Agnostic Cohort | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 2 |
| Not Hispanic or Latino | 7 | 14 | 21 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Melanoma Cohort | Tissue Agnostic Cohort | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 5 | 1 | 6 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 3 | 10 | 13 |
| More than one race | 0 | 2 | 2 |
| Unknown or Not Reported | 0 | 2 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2021 to primary completion in Jul 2024, 35 months.
Results were first posted in Oct 2025, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tovorafenib
Day One Biopharmaceuticals, Inc.